Literature DB >> 28078823

Hippo vs. Crab: tissue-specific functions of the mammalian Hippo pathway.

Miki Nishio1,2, Tomohiko Maehama1, Hiroki Goto2, Keisuke Nakatani2, Wakako Kato2, Hirofumi Omori2, Yosuke Miyachi2, Hideru Togashi1, Yohei Shimono1, Akira Suzuki1,2.   

Abstract

The Hippo signaling pathway is a vital suppressor of tumorigenesis that is often inactivated in human cancers. In normal cells, the Hippo pathway is triggered by external forces such as cell crowding, or changes to the extracellular matrix or cell polarity. Once activated, Hippo signaling down-regulates transcription supported by the paralogous cofactors YAP1 and TAZ. The Hippo pathway's functions in normal and cancer biology have been dissected by studies of mutant mice with null or conditional tissue-specific mutations of Hippo signaling elements. In this review, we attempt to systematically summarize results that have been gleaned from detailed in vivo characterizations of these mutants. Our goal is to describe the physiological roles of Hippo signaling in several normal organ systems, as well as to emphasize how disruption of the Hippo pathway, and particularly hyperactivation of YAP1/TAZ, can be oncogenic.
© 2017 The Authors Genes to Cells published by Molecular Biology Society of Japan and John Wiley & Sons Australia, Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28078823     DOI: 10.1111/gtc.12461

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  7 in total

1.  [YAP1 knockdown suppresses the proliferation, migration and invasion of human nasopharyngeal carcinoma cells].

Authors:  Yaqing Zhou; Rong Yang; Gang Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-03-30

2.  Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.

Authors:  Hirotoshi Soyama; Miki Nishio; Junji Otani; Toshiko Sakuma; Shintaro Takao; Shigeo Hara; Takaaki Masuda; Koshi Mimori; Shinya Toyokuni; John P Lydon; Kazuwa Nakao; Hiroshi Nishina; Takumi Fukumoto; Tomohiko Maehama; Akira Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-11       Impact factor: 12.779

Review 3.  A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy.

Authors:  Masahiro Shibata; Kendall Ham; Mohammad Obaidul Hoque
Journal:  Int J Cancer       Date:  2018-07-24       Impact factor: 7.396

4.  Blocking circ_0014130 suppressed drug resistance and malignant behaviors of docetaxel resistance-acquired NSCLC cells via regulating miR-545-3p-YAP1 axis.

Authors:  Dongjie Du; Xiaoci Cao; Xinbo Duan; Xianbo Zhang
Journal:  Cytotechnology       Date:  2021-05-25       Impact factor: 2.040

5.  YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma.

Authors:  Hirofumi Omori; Miki Nishio; Muneyuki Masuda; Yosuke Miyachi; Fumihito Ueda; Takafumi Nakano; Kuniaki Sato; Koshi Mimori; Kenichi Taguchi; Hiroki Hikasa; Hiroshi Nishina; Hironori Tashiro; Tohru Kiyono; Tak Wah Mak; Kazuwa Nakao; Takashi Nakagawa; Tomohiko Maehama; Akira Suzuki
Journal:  Sci Adv       Date:  2020-03-18       Impact factor: 14.136

6.  Integrated Transcriptomic Analysis Reveals a Distinctive Role of YAP1 in Extramedullary Invasion and Therapeutic Sensitivity of Multiple Myeloma.

Authors:  Bo Zheng; Wei Sun; Ke Yi; Yajun Zhang; Liangzhe Wang; Hongyan Lan; Chong Zhang; Hongming Xian; Rong Li
Journal:  Front Oncol       Date:  2022-01-04       Impact factor: 6.244

Review 7.  The role of Hippo-YAP signaling in squamous cell carcinomas.

Authors:  Tomohiko Maehama; Miki Nishio; Junji Otani; Tak Wah Mak; Akira Suzuki
Journal:  Cancer Sci       Date:  2020-12-09       Impact factor: 6.518

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.